#C1207N 3CLPro T21I + T304I Expression Kit

3CL^pro (M^pro) T21I + T304I mutation Expression Kit

The T21I T304I variant emerged during escape studies under nirmatrelvir inhibition (Zhou et al. 2022). Using a short-term concentration response treatment in VeroE6 cells against the escape mutant T21I T304I, researchers observed a 5.9-fold shift in EC₅₀ resistance to nirmatrelvir (Zhou et al. 2022). Pfizer reported a 3 to 8-fold increase in EC₅₀ to nirmatrelvir using a biochemical assay (Pfizer Laboratories 2022).  

• Identify protease inhibitors that maintain efficacy against the T21I + T304I mutation
• Easy co-expression with our 3CLglow and 3CLglowUp sensors
• Cost effective screening with minimal safety requirements (BSL-1)

Materials in the Kit:

• 3CL^pro T21I + T304I in BacMam
• Sodium Butyrate, 500 mM in H₂O

References:

Pfizer Laboratories. (2022). (rep.). FACT SHEET FOR HEALTHCARE PROVIDERS:  EMERGENCY USE AUTHORIZATION FOR PAXLOVID. Retrieved from https://labeling.pfizer.com/ShowLabeling.aspx?id=16474.

Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Tjørnelund, H. D., Binderup, A., Duarte Hernandez, C. R., Fernandez-Antunez, C., Offersgaard, A., Fahnøe, U., Peters, G. H., Ramirez, S., Bukh, J., & Gottwein, J. M. (2022). Nirmatrelvir-resistant SARS-COV-2 variants with high fitness in an infectious cell culture system. Science Advances, 8(51). https://doi.org/10.1126/sciadv.add7197